Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Vertex Pharmaceuticals Incorporated is a biotechnology business based in the US. Vertex Pharmaceuticals Incorporated shares (VRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Vertex Pharmaceuticals Incorporated employs 3,400 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$202.57 - $306.08|
|50-day moving average||$215.51|
|200-day moving average||$219.92|
|Wall St. target price||$284.68|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$10.49|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Vertex Pharmaceuticals Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vertex Pharmaceuticals Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Vertex Pharmaceuticals Incorporated's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Vertex Pharmaceuticals Incorporated shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Vertex Pharmaceuticals Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.3871. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Vertex Pharmaceuticals Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Vertex Pharmaceuticals Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.1 billion.
The EBITDA is a measure of a Vertex Pharmaceuticals Incorporated's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$6.4 billion|
|Operating margin TTM||47.26%|
|Gross profit TTM||$3.6 billion|
|Return on assets TTM||18.04%|
|Return on equity TTM||35.77%|
|Market capitalisation||$55.7 billion|
TTM: trailing 12 months
There are currently 4.9 million Vertex Pharmaceuticals Incorporated shares held short by investors – that's known as Vertex Pharmaceuticals Incorporated's "short interest". This figure is 17.9% up from 4.2 million last month.
There are a few different ways that this level of interest in shorting Vertex Pharmaceuticals Incorporated shares can be evaluated.
Vertex Pharmaceuticals Incorporated's "short interest ratio" (SIR) is the quantity of Vertex Pharmaceuticals Incorporated shares currently shorted divided by the average quantity of Vertex Pharmaceuticals Incorporated shares traded daily (recently around 1.7 million). Vertex Pharmaceuticals Incorporated's SIR currently stands at 2.81. In other words for every 100,000 Vertex Pharmaceuticals Incorporated shares traded daily on the market, roughly 2810 shares are currently held short.
However Vertex Pharmaceuticals Incorporated's short interest can also be evaluated against the total number of Vertex Pharmaceuticals Incorporated shares, or, against the total number of tradable Vertex Pharmaceuticals Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vertex Pharmaceuticals Incorporated's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Vertex Pharmaceuticals Incorporated shares in existence, roughly 20 shares are currently held short) or 0.0189% of the tradable shares (for every 100,000 tradable Vertex Pharmaceuticals Incorporated shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vertex Pharmaceuticals Incorporated.
Find out more about how you can short Vertex Pharmaceuticals Incorporated stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Vertex Pharmaceuticals Incorporated.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 30.84
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Vertex Pharmaceuticals Incorporated's overall score of 30.84 (as at 12/31/2018) is nothing to write home about – landing it in it in the 44th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Vertex Pharmaceuticals Incorporated is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 5.65/100
Vertex Pharmaceuticals Incorporated's environmental score of 5.65 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals Incorporated is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 24.22/100
Vertex Pharmaceuticals Incorporated's social score of 24.22 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals Incorporated is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 12.46/100
Vertex Pharmaceuticals Incorporated's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Vertex Pharmaceuticals Incorporated is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Vertex Pharmaceuticals Incorporated scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Vertex Pharmaceuticals Incorporated has, for the most part, managed to keep its nose clean.
|Total ESG score||30.84|
|Total ESG percentile||44|
|Environmental score percentile||8|
|Social score percentile||8|
|Governance score percentile||8|
|Level of controversy||2|
We're not expecting Vertex Pharmaceuticals Incorporated to pay a dividend over the next 12 months.
Vertex Pharmaceuticals Incorporated's shares were split on a 2:1 basis on 23 August 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Vertex Pharmaceuticals Incorporated shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Vertex Pharmaceuticals Incorporated shares which in turn could have impacted Vertex Pharmaceuticals Incorporated's share price.
Over the last 12 months, Vertex Pharmaceuticals Incorporated's shares have ranged in value from as little as $202.565 up to $306.08. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vertex Pharmaceuticals Incorporated's is 0.6701. This would suggest that Vertex Pharmaceuticals Incorporated's shares are less volatile than average (for this exchange).
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc. ; Moderna, Inc. ; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.